Liquidia Corporation
LQDA
Rang in aandelen
#4682
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Aandeelprijs
$36.17
Marktkapitalisatie
$3.24B
Verandering (1 dag)
5.98%
Verandering (1 jaar)
48.00%
Land
US
Handel Liquidia Corporation (LQDA)
Categorie
Healthcare
P/S-ratio voor Liquidia Corporation (LQDA)
P/S-ratio op October 2026 TTM: 6.74
Volgens de meest recente financiële rapporten en aandelenkoers van Liquidia Corporation is de huidige P/S-ratio (TTM) 6.74. Eind 2023 had het bedrijf een P/S-ratio van 44.71.
P/S-ratiohistoriek voor Liquidia Corporation van 2016 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 6.74 | -89.81% |
| 2024 | 66.13 | 47.92% |
| 2023 | 44.71 | 83.47% |
| 2022 | 24.37 | 29.46% |
| 2021 | 18.82 | -86.07% |
| 2020 | 135.16 | 1,280.87% |
| 2019 | 9.79 | -82.92% |
| 2018 | 57.32 | 336.47% |
| 2017 | 13.13 | 82.10% |
| 2016 | 7.21 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.31 | 53.04% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 124.46% |
US
|
